Figure 4
From: PRMT5 is a therapeutic target in choroidal neovascularization
PR5-LL-CM01 is antiangiogenic in vitro. (a) Structure of PRMT5 inhibitor PR5-LL-CM0127. (b,c) PR5-LL-CM01 is antiproliferative at 48 h of treatment on HRECs (b) and on iCEC2 cells (c). Mean ± SEM, n = 3 technical replicates. Representative data from three biological replicates. PR5-LL-CM01 dose-dependently decreases cells in S-phase and increases cells in G0/G1 after 24 h of treatment in (d,f) HRECs, and in (e,g) iCEC2 cells. Mean ± SEM of percentage of cells, n = 3 biological replicates.
